Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 3/20 | 0.44 |
| ▸ | HINT1 | P49773 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PNP | P00491 | 1/20 | 0.38 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL930787 | 1.00 | NT5E (0.44) | NT5EHINT1LMNAALDH1A1TP53 | |
| SCHEMBL930789 | 1.00 | NT5E (0.44) | NT5EHINT1LMNAALDH1A1TP53 | |
| SCHEMBL6365090 | 1.00 | NT5E (0.44) | NT5EHINT1LMNAALDH1A1TP53 | |
| SCHEMBL30378647 | 1.00 | NT5E (0.44) | NT5EHINT1LMNAALDH1A1TP53 | |
| SCHEMBL19777955 | 1.00 | NT5E (0.44) | NT5EHINT1LMNAALDH1A1TP53 | |
| SCHEMBL930786 | 1.00 | NT5E (0.44) | NT5EHINT1LMNAALDH1A1TP53 | |
| SCHEMBL14652919 | 1.00 | NT5E (0.44) | NT5EHINT1LMNAALDH1A1TP53 | |
| SCHEMBL17453217 | 1.00 | NT5E (0.44) | NT5EHINT1LMNAALDH1A1TP53 | |
| SCHEMBL2484115 | 0.94 | NT5E (0.44) | NT5EHINT1LMNAALDH1A1TP53 | |
| SCHEMBL2484116 | 0.94 | NT5E (0.44) | NT5EHINT1LMNAALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542505-B1 | Substituted RIG-I agonists: compositions and methods thereof | MERCK SHARP & DOHME LLC (US) | 2023-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542505-B1 | Substituted RIG-I agonists: compositions and methods thereof | MAVS, TLR3, DDX18 | NT5E 562/4885HINT1 2123/4885LMNA 2612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.